Hepatocytes are the primary working cells of the liver, making up roughly 80 percent of its mass and performing most of the organ’s metabolic, detoxification, and synthetic tasks. When your liver regulates blood sugar, breaks down a medication, manufactures blood-clotting proteins, or produces bile, hepatocytes are doing the heavy lifting. Their unusual structure, their ability to regenerate after injury, and the ways they fail in disease together explain much of what keeps the liver healthy or drives it toward damage.
How Hepatocytes Are Built
Most cells in your body have a straightforward orientation: one side faces outward and the other sits on a supporting surface. Hepatocytes break this mold. Each cell has multiple distinct surfaces doing different jobs at the same time. The basal side faces tiny blood vessels called sinusoids, where it picks up nutrients, hormones, and oxygen from the bloodstream. One or more apical surfaces, shared with neighboring hepatocytes, form narrow channels called bile canaliculi, where bile is secreted. Tight junctions seal the gaps between these zones so that blood and bile never mix.1PubMed Central. Structural and functional hepatocyte polarity and liver disease A single hepatocyte can participate in several bile canaliculi while simultaneously presenting multiple basal faces to the sinusoidal blood supply.2PubMed Central. Hepatocyte polarity
This arrangement, sometimes called multipolarization, is rare among epithelial cells. In mouse liver tissue, the apical band that forms each canaliculus is only about 2 micrometers wide, encircling part of the cell surface like a thin belt.3Journal of Biological Chemistry. Hepatocyte polarity establishment and apical lumen formation are organized by Par3, Cdc42, and aPKC in conjunction with Lgl That compact geometry is essential: the bile canaliculus needs to collect bile secretions without leaking toxic bile acids back into the blood, while the sinusoidal surface needs maximum exposure for absorbing and releasing substances. When this polarity breaks down, as it does in some liver diseases, bile flow stalls and toxic compounds accumulate.
Polyploidy, an Unusual Genetic Feature
Most human cells carry two copies of each chromosome. Hepatocytes often carry four, eight, or even more. This state, called polyploidy, has been documented in liver tissue since the 1940s, but researchers are still working out exactly why it happens and what it does.4PubMed Central. The origins and functions of hepatic polyploidy Current evidence points toward polyploidy as a protective feature. When liver cells face toxic stress, having extra copies of the genome may let them adapt genetically without needing to divide. There is also growing evidence that increased ploidy is a hallmark of liver inflammation and may guard against the development of liver cancer.5PubMed. Polyploidy control in hepatic health and disease The flip side is that it makes hepatocyte biology harder to study in the lab, because these cells do not behave like standard diploid cells when you try to culture or transplant them.
Managing Blood Sugar
If you have not eaten in several hours, your blood sugar does not crash to zero. You can thank your hepatocytes. The liver is the body’s central glucose thermostat, controlling blood sugar by toggling between two modes: storing glucose as glycogen when you have just eaten, and releasing glucose by breaking glycogen back down or building new glucose molecules when you are fasting.6PubMed Central. Molecular pathophysiology of hepatic glucose production
Hormones orchestrate the switch. After a meal, insulin tells hepatocytes to pull glucose out of the blood and pack it into glycogen. Between meals, glucagon flips the instruction, prompting hepatocytes to release stored glucose and, if glycogen runs low, to manufacture fresh glucose from smaller molecules like amino acids and lactate.7PubMed. Hepatocytes: critical for glucose homeostasis When this signaling goes wrong, as it does in insulin resistance and type 2 diabetes, hepatocytes keep pumping glucose into the blood even when blood sugar is already high.
Fat Handling and Protein Production
Glucose is only part of the metabolic picture. Hepatocytes are also central to lipid metabolism. The liver packages fats into very-low-density lipoproteins (VLDL) and ships them out to the rest of the body, and it also pulls fatty acids and lipoproteins back in for processing.8PubMed Central. Metabolic-associated fatty liver disease and lipoprotein metabolism When fatty acid intake outpaces the liver’s ability to export or burn those fats, lipid droplets accumulate inside hepatocytes, setting the stage for fatty liver disease.
Beyond fat metabolism, hepatocytes are the body’s primary factory for plasma proteins. Albumin, the most abundant protein in blood, is made almost exclusively by hepatocytes. So are fibrinogen, a key clotting protein, and transferrin, which ferries iron through the bloodstream.9Biochemical Journal. Albumin, fibrinogen and transferrin synthesis in isolated rat hepatocyte suspensions Coagulation factor IX, the clotting factor missing in hemophilia B, is produced solely by hepatocytes; no other cell type in the body makes it.10PubMed Central. Hepatocyte Is a Sole Cell Type Responsible for the Production of Coagulation Factor IX In Vivo This is why severe liver disease so often leads to bleeding problems and fluid imbalances: the cell responsible for making these proteins is damaged or destroyed.
Detoxification and Drug Metabolism
Every medication you swallow eventually passes through the liver, and hepatocytes are where most of the chemical processing happens. Drug metabolism is conventionally divided into two phases. Phase I reactions modify the drug molecule, typically by adding a reactive group, while Phase II reactions attach a bulky, water-soluble tag that makes the compound easier to excrete.11PubMed. Drug Metabolism in the Liver The enzymes responsible for these steps, including the cytochrome P450 family for Phase I and various transferases for Phase II, are concentrated in hepatocytes.12PubMed. Inter-donor variability of phase I/phase II metabolism of three reference drugs in cryopreserved primary human hepatocytes in suspension and monolayer
One reason drug reactions vary so much from person to person is that the levels and activities of these enzymes differ between individuals. Even in carefully controlled laboratory settings, hepatocytes from different human donors show wide variation in how fast they process the same drug.12PubMed. Inter-donor variability of phase I/phase II metabolism of three reference drugs in cryopreserved primary human hepatocytes in suspension and monolayer Genetics, age, other medications, and the health of the liver itself all contribute to this variability. It is also worth noting that Phase I processing can sometimes produce a metabolite that is more toxic than the original drug, which is one mechanism behind drug-induced liver injury.
Bile Production and Ammonia Clearance
Bile is often treated as a digestive aid, but it also serves as a major waste-disposal route. Hepatocytes synthesize bile acids, then actively pump them across their apical membranes into the bile canaliculi using dedicated transporter proteins.13PubMed Central. Bile acid transporters From there, bile flows into larger ducts, collects in the gallbladder, and eventually enters the intestine. The bile acids emulsify dietary fats, but they also carry bilirubin, cholesterol, and drug metabolites out of the body. When the main export pump for bile acids is defective, hepatocytes compensate by rerouting bile acids out through their basolateral (blood-facing) side and simultaneously dialing down new bile acid synthesis.14PubMed Central. Modeling Human Bile Acid Transport and Synthesis in Stem Cell-Derived Hepatocytes with a Patient-Specific Mutation
Hepatocytes also handle another critical waste product: ammonia. Protein breakdown throughout the body generates ammonia, which is neurotoxic at high concentrations. Hepatocytes convert ammonia into urea through a multi-step cycle, and the urea is then safely excreted by the kidneys. This process depends in part on specialized water channels in mitochondrial membranes that facilitate the uptake of ammonia, particularly under the influence of the hormone glucagon.15PubMed. Ammonia detoxification via ureagenesis in rat hepatocytes involves mitochondrial aquaporin-8 channels When the liver fails, ammonia levels rise sharply, leading to confusion, disorientation, and in severe cases, coma.
Zonation Along the Liver Lobule
Not all hepatocytes do the same job at the same time. Blood flows through the liver lobule from the portal triad at the edge toward the central vein in the middle, and along that route, oxygen and nutrient concentrations gradually drop. Hepatocytes near the incoming blood are bathed in oxygen-rich, nutrient-dense blood, while those near the central vein see blood that has already been partially depleted. The liver exploits this gradient by assigning different metabolic tasks to hepatocytes based on their position, a phenomenon called metabolic zonation.16JHEP Reports. Distinct hepatocyte identities in liver homeostasis and regeneration
In practice, this means that ammonia detoxification and gluconeogenesis are concentrated in the oxygen-rich periportal zone, while bile acid synthesis and certain drug-metabolizing enzymes are more active near the central vein. The zonation pattern is not fixed; it can shift in response to injury or metabolic demand. This spatial division of labor explains why different toxins and diseases damage different zones of the lobule. Acetaminophen toxicity, for instance, preferentially kills hepatocytes in the central zone, where the enzyme that converts acetaminophen into its toxic metabolite is most abundant.
How the Liver Regenerates
The liver’s capacity to regrow after injury is extraordinary. Remove up to two-thirds of a rodent liver and the remaining tissue will restore its original mass within days. The default pathway is straightforward: surviving hepatocytes re-enter the cell cycle and divide until the lost tissue is replaced.17PubMed Central. Triggering Mechanisms of Hepatocyte Repopulation during Liver Regeneration This is not the same as growing a new organ from scratch; the liver does not regenerate from a single spot. Instead, hepatocytes throughout the remnant proliferate roughly in proportion to how much tissue was lost.
When the damage is so severe or chronic that mature hepatocytes cannot divide, a backup system kicks in. Hepatic progenitor cells, sometimes called oval cells in rodent research, can activate and differentiate into either hepatocytes or the cells that line the bile ducts.18PubMed. Hepatic Progenitor Cells in Action: Liver Regeneration or Fibrosis? This progenitor response typically appears in the context of chronic viral hepatitis, alcoholic liver disease, or exposure to drugs that block hepatocyte division.19PubMed Central. Hepatic progenitor cell activation in liver repair It is slower and less efficient than hepatocyte self-duplication, and in some cases the activation of progenitor cells is itself linked to fibrosis rather than clean repair.
Regeneration is not a solo act by hepatocytes alone. The non-parenchymal cells of the liver, including the endothelial cells lining the sinusoids, the resident immune cells called Kupffer cells, and the stellate cells that store vitamin A and produce collagen, all coordinate with hepatocytes through signaling networks. Early signals like tumor necrosis factor and growth factors trigger hepatocyte entry into the cell cycle, while endothelial cells and stellate cells help remodel the tissue architecture as it regrows.20PubMed Central. Cellular crosstalk during liver regeneration: unity in diversity
When Hepatocytes Get Sick
Metabolic dysfunction-associated steatotic liver disease, or MASLD (formerly known as NAFLD), is now the most common chronic liver condition worldwide. The core problem at the cell level is lipid overload. When insulin resistance and excess fat cause more fatty acids to flow into the liver than hepatocytes can process or export, fat accumulates inside the cells. Over time this triggers mitochondrial damage, oxidative stress, and inflammation.21PubMed. Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease If the lipotoxic stress is chronic, it activates cell-death pathways and inflammatory genes, pushing the disease from simple fat accumulation toward active tissue damage and scarring.22PubMed. Nutrigenomics of fat-soluble vitamins and micronutrients in hepatocyte lipotoxicity and MASLD
Hepatocyte death in liver disease does not happen randomly. Apoptosis, the controlled self-destruction of a cell, is the most studied pathway, but hepatocytes can also die through the endoplasmic reticulum stress response or through oxidative-stress-driven mechanisms.23PubMed Central. Mechanism of Hepatocyte Apoptosis The pattern and extent of hepatocyte death help determine whether the liver can regenerate cleanly or instead lays down scar tissue, eventually progressing to cirrhosis.
Viral Hijacking of Hepatocytes
Hepatitis B and hepatitis C viruses both target hepatocytes specifically, but they use different doors to get in. Hepatitis B virus (HBV) exploits a bile acid transporter called NTCP on the hepatocyte surface. This transporter normally imports bile acids from the blood; HBV’s envelope proteins bind to it and ride it into the cell.24PubMed Central. Hepatitis B Virus Entry into Cells The discovery of NTCP as the entry receptor was a major breakthrough, because it opened the door to developing drugs that block viral entry by competing for the same transporter.25PubMed Central. Hepatitis B virus entry, assembly, and egress
Hepatitis C virus (HCV) takes a more complex route, engaging multiple host-cell proteins in sequence: a receptor called CD81, a scavenger receptor, and tight-junction proteins like claudin-1 and occludin.26PubMed. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies The reliance on tight-junction proteins is particularly interesting because those junctions sit between hepatocytes, meaning the virus may use the cell’s own polarity machinery to gain access. Understanding these entry mechanisms has been central to the development of antivirals for both infections.
Hepatocyte Aging and Senescence
As people age, some hepatocytes stop dividing permanently while remaining metabolically active, a state called cellular senescence. These senescent hepatocytes accumulate over the decades and are implicated in the liver’s gradually declining regenerative capacity, as well as in the progression of chronic diseases like cirrhosis and liver cancer.27PubMed Central. Hepatic senescence, the good and the bad
Recent spatial mapping of human livers has revealed that senescent hepatocytes are not scattered randomly. Those expressing the senescence marker p21 tend to cluster near the portal tracts, while a distinct aging-associated population forms spatial clusters potentially mediated by cell-adhesion molecules. Chemotherapy dramatically amplifies senescence, increasing the proportion of senescent hepatocytes roughly five-fold compared with normal aging.28Cell Genomics. High-resolution spatial mapping and multi-omic profiling reveal cell-type-specific senescence landscapes in human and mouse livers In the context of MASLD specifically, senescent hepatocytes appear to increase sharply as fibrosis advances: one analysis found that about 8 percent of hepatocytes in advanced fibrotic livers bore a senescence gene signature, versus only 0.13 percent in healthy tissue.29Nature Communications. Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction These senescent cells release inflammatory signals that can damage surrounding tissue, making them an attractive target for drugs that selectively clear them, an approach known as senolytic therapy.
Micronutrient Storage and Metal Homeostasis
The liver is the body’s main warehouse for several essential vitamins and trace metals, and hepatocytes handle the logistics. Iron, copper, and zinc are all efficiently extracted from the blood by hepatocytes, stored, and redistributed as needed. The liver uses copper to produce ceruloplasmin, a circulating enzyme that helps release iron from its storage sites around the body.30PubMed Central. Intersection of Iron and Copper Metabolism in the Mammalian Intestine and Liver Zinc and copper share at least one common transport pathway into hepatocytes, which means that a large surplus of one can interfere with the uptake of the other.31PubMed. Mechanisms of metal transport across liver cell plasma membranes
This interconnection has practical consequences. High-dose zinc supplementation, for instance, has long been used as a strategy to reduce copper absorption in conditions like Wilson disease, where copper accumulates to toxic levels. Conversely, chronic liver disease can upset iron storage, leading to either overload (as in hemochromatosis) or redistribution problems that worsen tissue damage. The hepatocyte’s ability to sense circulating metal levels and adjust its transport accordingly makes it a key regulatory node for trace-element balance throughout the body.
Bioartificial Livers and Hepatocyte Transplantation
Because hepatocytes perform so many irreplaceable functions, one long-running goal in medicine has been to use them outside the body to support patients in acute liver failure. Bioartificial liver (BAL) devices work by circulating the patient’s blood or plasma through a cartridge containing living hepatocytes, which perform detoxification and synthesis that the failing liver cannot. In pig models of acute liver failure, treatment with a BAL containing human hepatocytes has restored liver function markers to normal within a week.32PubMed Central. Bioartificial liver: Where lies the path ahead—A review
A study published in Cell Stem Cell reported that a BAL using human-induced hepatocytes manufactured under clinical-grade conditions showed a survival benefit in a porcine model, and an early investigator-initiated study in seven patients who had undergone extended liver resection found the device to be safe and associated with improved liver function and regeneration.33Cell Stem Cell. GMP-compliant manufactured human-induced hepatocytes enable a bioartificial liver for treating acute liver failure A more recent approach used gene-edited pig hepatocytes with a key immunogenicity gene knocked out, co-cultured with human endothelial cells to form liver organoids. When tested with plasma from patients with acute-on-chronic liver failure, the system reduced ammonia and bilirubin levels and restored metabolic balance more effectively than non-biological support devices.34PubMed Central. Bioartificial Livers Developed From Gene-Edited Pig Hepatocyte Organoids Improve Amino Acid and Lipid Profiles in the Plasma of Patients With Liver Failure These are still early-stage technologies, but the pace of progress suggests that reliable, scalable BAL devices could eventually reduce the dependence on scarce donor livers for transplant.
Liver-on-a-Chip and Drug Safety Testing
Predicting whether a new drug will harm the liver before it reaches patients has historically been one of the hardest problems in pharmaceutical development. Traditional cell cultures lose key hepatocyte functions within days, and animal livers metabolize drugs differently than human livers do. Organ-on-a-chip technology is changing this. These microfluidic devices culture hepatocytes and other liver cell types on tiny chips that mimic blood flow and tissue architecture, keeping cells functional for weeks.
In a performance assessment of one such Liver-Chip platform, the device correctly identified toxic and non-toxic drugs across a blinded set of 27 compounds with 87 percent sensitivity and 100 percent specificity.35Communications Medicine. Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology Newer high-throughput systems have pushed this further, screening libraries of over 150 known toxic compounds in 96-well plate-based chip formats that use gravity-driven flow to maintain hepatocyte organoids.36Materials Today Bio. Liver-on-chips for drug discovery and development If these platforms prove reliable at scale, they could reduce both animal testing and the number of drugs that fail late in clinical trials due to unexpected liver toxicity, a failure mode that currently costs the pharmaceutical industry billions of dollars annually and, more importantly, puts trial participants at risk.